BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12086871)

  • 1. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients.
    Elledge SJ; Amon A
    Cancer Cell; 2002 Mar; 1(2):129-32. PubMed ID: 12086871
    [No Abstract]   [Full Text] [Related]  

  • 2. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
    Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
    Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of BRCA1 tumor suppression.
    Silver DP; Livingston DM
    Cancer Discov; 2012 Aug; 2(8):679-84. PubMed ID: 22843421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A structural bioinformatics approach to explore the interactions of P53 and BRCA1 gene products on ovarian and breast cancer.
    Parija S; Kumar A
    Int J Bioinform Res Appl; 2011; 7(1):1-14. PubMed ID: 21441093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1: what do we know? What do we think we know? What do we really need to know?
    Buller RE
    Gynecol Oncol; 2000 Mar; 76(3):291-3. PubMed ID: 10684698
    [No Abstract]   [Full Text] [Related]  

  • 6. Possible function found for breast cancer genes.
    Marx G
    Science; 1997 Apr; 276(5312):531-2. PubMed ID: 9148411
    [No Abstract]   [Full Text] [Related]  

  • 7. BRCA1 in breast and ovarian cancer predisposition.
    Billack B; Monteiro AN
    Cancer Lett; 2005 Sep; 227(1):1-7. PubMed ID: 16051027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of hereditary breast and ovarian cancers.
    Tommasi S
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii7. PubMed ID: 24131975
    [No Abstract]   [Full Text] [Related]  

  • 9. Deciphering the BRCA1 Tumor Suppressor Network.
    Jiang Q; Greenberg RA
    J Biol Chem; 2015 Jul; 290(29):17724-17732. PubMed ID: 26048987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair: Decision at the break point.
    Boulton SJ
    Nature; 2010 May; 465(7296):301-2. PubMed ID: 20485424
    [No Abstract]   [Full Text] [Related]  

  • 11. BAP1, a candidate tumor suppressor protein that interacts with BRCA1.
    Jensen DE; Rauscher FJ
    Ann N Y Acad Sci; 1999; 886():191-4. PubMed ID: 10667217
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer. Complicated supercomplexes.
    Livingston DM
    Science; 2009 May; 324(5927):602-3. PubMed ID: 19407191
    [No Abstract]   [Full Text] [Related]  

  • 13. BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer.
    Sedic M; Kuperwasser C
    Cell Cycle; 2016; 15(5):621-7. PubMed ID: 26822887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 regulation of transcription.
    Rosen EM; Fan S; Ma Y
    Cancer Lett; 2006 May; 236(2):175-85. PubMed ID: 15975711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of hereditary and sporadic ovarian cancers reveals unique BRCA1 and BRCA2 signatures.
    Hedenfalk IA
    J Natl Cancer Inst; 2002 Jul; 94(13):960-1. PubMed ID: 12096075
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
    Miramar MD; Calvo MT; Rodriguez A; Antón A; Lorente F; Barrio E; Herrero A; Burriel J; García de Jalón A
    Breast Cancer Res Treat; 2008 Nov; 112(2):353-8. PubMed ID: 18176857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control.
    Stefansson OA; Esteller M
    Breast Cancer Res; 2012 Mar; 14(2):304. PubMed ID: 22423979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brca1 and differentiation.
    Kubista M; Rosner M; Miloloza A; Hofer K; Prusa AR; Kroiss R; Marton E; Hengstschläger M
    Mutat Res; 2002 Dec; 512(2-3):165-72. PubMed ID: 12464350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.